Trastuzumab emtansine (T-DM1), an anti-erb-b2 receptor tyrosine kinase 2 (HER2) antibody-drug conjugate, has been shown to significantly improve survival in HER2-positive breast cancer. We report a phase II trial of T-DM1 monotherapy in relapsed NSCLC with documented HER2 positivity (an immunohistochemistry [IHC] score of 3þ, both an IHC score of 2þ and fluorescence in situ hybridization positivity, or exon 20 mutation). This study was terminated early because of limited efficacy. The demographic characteristics in the 15 assessable patients were as follows: median age, 67 years; male sex, 47%; performance status of 0 to 1, 80%; HER2 status IHC 3þ, 33%; HER status IHC 2þ/fluorescence in situ hybridization-positive, 20%; and exon 20 mutation, 47%. The median number of delivered cycles was 3 (range 1-11). One patient achieved a partial response with an objective response rate of 6.7% (90% confidence interval: 0.2-32.0). With a median follow-up time of 9.2 months, the median progressionfree survival time and median survival time were 2.0 and 10.9 months, respectively. Grade 3 or 4 adverse events included thrombocytopenia (40%) and hepatotoxicity (20%) without any treatment-related deaths. T-DM1 had a limited efficacy for HER2-positive NSCLC in our cohort. Applying the concept of precision medicine to tumors appears challenging; thus, additional molecular approaches are warranted.
Introduction
Recent driver oncogene-based precision therapy has dramatically changed the treatment strategy for NSCLC, representatively targeting EGFR and ALK receptor tyrosine kinase gene (ALK) aberrations. However, outcomes in other lung cancers remain poor even with standard chemotherapy. 1, 2 Consequently, further development of novel oncogenes and corresponding targeted therapeutic agents is warranted.
In addition, erb-b2 receptor tyrosine kinase 2 (HER2) aberrations have been detected, accounting for 4.7% to 10% of NSCLC in terms of grade 3þ HER2 immunohistochemistry (IHC) expression. 3 Additionally, the large epidemiological studies have identified tumors with positive HER2 fluorescence in situ hybridization (FISH) in 1.7% and HER2-mutant tumors in 3.6%. 4 Trastuzumab emtansine (T-DM1) is a novel antibodydrug conjugate that uses trastuzumab, an anti-HER2 antibody, to deliver the maytansinoid antimicrotubule agent DM1, which binds to microtubules in a manner similar to that of vinca alkaloids. 5 T-DM1 has been shown to confer a survival benefit over the standard regimen applied in HER2-positive, relapsed breast cancer. 6 As for NSCLC, the Calu 3 lung carcinoma cell line (HER2-IHC 3þ) showed preclinically dose-dependent inhibition of cell growth after T-DM1 treatment. 5 Moreover, lung tumors with erb-b2 receptor tyrosine kinase 2 gene (HER2) insertion mutations in exon 20, a confirmed driver oncogene, showed dramatic shrinkage with HER2-targeted therapy. 7 These studies suggested that T-DM1 might be effective against both HER2-positive lung and breast cancers.
However, few prospective studies of HER2-targeted therapy for lung cancer have been conducted, prompting us to launch this phase II trial.
Methods

Study Population and Intervention
Patients who met the eligibility criteria, including HER2 positivity, 8 were enrolled for registration at three institutes in Japan: Yamaguchi-Ube Medical Centre, Shikoku Cancer Centre, and Okayama University Hospital. T-DM1 was kindly provided by Chugai Pharmaceuticals. Patients had to have had one or more lines of prior chemotherapy. Written informed consent was obtained from all patients before applying the study procedures. This study was approved by the institutional review boards.
Patients received T-DM1 intravenously, at a dose of 3.6 mg/kg over 90 minutes on day 1 of each 21-day cycle until the disease progressed or unmanageable toxic effects developed, as similar to the protocol for breast cancer. 
HER2 Tests
HER2 status was assessed in the laboratory (SRL, Tokyo, Japan) by using tumor formalin-fixed, paraffinembedded archived tissues; no cytologic specimens were allowed, but biopsy or surgical specimens were. The level of HER2 protein expression was determined by IHC by using the Ventana I-VIEW PATHWAY anti-HER-2/neu (4B5) (Roche, Basel, Switzerland). 9 IHC scores of 3þ and 2þ were considered strongly and weakly positive, respectively.
9 FISH assays were also performed using the PathVysion HER-2 DNA probe kit (Vysis/Abbott Laboratories, Downers Grove, IL) to ascertain negativity or positivity according to a cutoff value of 2.0 (of the median ratio of HER2 to chromosome 17 copy numbers). We conducted a separate validation study to review the IHC and FISH specimens to define their positivity (unpublished data, Hotta K, 2017) . Mutation analysis was performed by direct sequencing at a central laboratory (Genetic Labo, Japan) to detect known mutations (M774_A775insAYVM, A775_G776insYVMA, G776L insC, G776V insC, and P780_Y781insGSP). 4 Finally, in this trial, HER2 was defined as positive in the presence of an IHC score of 3þ, an IHC score of 2þ and FISH positivity, or an exon 20 insertion mutation.
Statistical Analysis
The primary end point was the objective response rate (ORR), which was centrally confirmed by three independent board members with the Response Evaluation Criteria in Solid Tumors (version 1.1) every 6 weeks. Secondary outcome end points included safety, overall survival, and progression-free survival (PFS). We considered the lower limit of interest to be 10%. 10 Assuming that a 20% or more increase in historical data in ORR would be clinically meaningful, we needed 30 patients with a one-sided a of 0.05 and 1-b of 0.8, considering a 10% dropout rate, according to the Simon minimax design. We also planned to conduct an interim analysis after the first 15 patients had been registered; early study termination would be considered if the ORR was obtained in no more than one patient. The confidence interval (CI) of the ORR was calculated with a confidence coefficient of two-tailed 90% and 95%.
Regarding the efficacy analysis, waterfall and swimmer plots were also produced. The PFS and overall survival times were calculated from the date of registration to the first documented date of disease progression and date of death, respectively, by the Kaplan-Meier method. Statistical analyses were conducted with STATA software (version 14.0, StataCorp LP, College Station, TX).
Results
Patients
This study was terminated early because of the limited efficacy, which did not satisfy the criteria in the interim analysis; this led to only 16 of the 30 patients planned being registered between September 2015 and November 2016. Among them, 15 were considered assessable for further analysis: one patient was excluded because of a protocol deviation in the registration process. The patients' characteristics are listed in Table 1 . Regarding HER2 status, 33% of cases were scored IHC 3þ, 20% were scored IHC 2þ/FISH positive, and 47% showed the mutations. All 15 patients were followed up sufficiently to allow assessment of the primary end point.
Treatment Delivery
The treatment delivery is summarized in Table 2 . The median delivered number of cycles to each patient was 3 ( Table 2 ). Four patients (27%) required dose reduction during the second cycle or later because of adverse events (AEs) (see Table 2 ). Treatment was ultimately discontinued in all patients, mainly on account of disease progression (see Table 2 ).
ORR and Survival
A partial response was centrally confirmed in a female patient with a HER2-mutant tumor (Table 3) . Thus, the ORR (the primary end point) was 6.7% (90% CI: 0.2%-32.0%, 95% CI: 0.3%-27.9%), whereas seven patients (46.7%) each had stable disease and progressive disease (Fig. 1A) . When patients were stratified by type of HER2 aberration, no tumor shrinkage was seen in the subgroup with an IHC score of 3þ or IHC 2þ/FISHpositive tumors (n ¼ 8) (Fig. 1B and Table 3 ). With a median follow-up time of 9.2 months, the median PFS time was 2.0 months (90% CI: 1.2-4.0, 95% CI: 1.4-4.0), whereas the median survival time was 10.9 months (90% CI: 2.3-, 95% CI: 4.4-12.0) ( Fig. 2A and B) .
Safety
All grade 3 to 4 AEs are listed in Table 4 . Almost all of the AEs were known ones, primarily thrombocytopenia (n ¼ 6 [40%]) and hepatotoxicity (n ¼ 3 [20%]). Among the 15 patients, there was no case of treatment-related death.
Grade 3 acute renal failure with a serum creatinine level of 3.08 mg/dL developed in one patient. The AE was 
Note: The objective response rate (i.e., the primary end point) was centrally confirmed by three independent extramural review board members and evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1) every 6 weeks. CR, complete response; PR, partial response; PD, progressive disease; HER2, erb-b2 receptor tyrosine kinase 2 IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
recovered to grade 0 within 1 week during provision of appropriate supportive care. Interstitial pneumonia was observed in one patient (grade 2) during the fifth cycle, as detected by computed tomography. No further examination with bronchoscopy was performed in this case and the AE was resolved shortly thereafter without any steroid or oxygen therapy but just discontinuation of T-DM1.
Discussion
In this study, 1 of 15 patients (6.7%) responded to T-DM1, which did not meet the primary end point (see Table 3 ). The median PFS and median survival times were 2.0 and 10.9 months, respectively. The AE profiles were almost the same as those obtained in trials for approval for use in breast cancer. 6 The investigational agent did not show high efficacy in this study (see Table 3 and Fig. 1 ), which is similar to the results of the very recent trials investigating HER2-targeted therapy in lung cancer (Supplementary Table 1 ). In particular, IHC 3þ or IHC 2þ/FISH-positive tumors were rarely responsive to the investigational agent in this study (see Fig. 1 and Table 3) . Although the precise reason remains unknown, it could be attributable to tumor heterogeneity, which was detected in 30% of the NSCLC cases. 11 It may be that only strongly HER2-immunostained cells were killed in the tumors after exposure to T-DM1, whereas the weakly stained cells might have escaped cell death and continued to grow. Unfortunately, we did not obtain or analyze tumor specimens at the time of disease progression. Further molecular analyses are warranted to elucidate the mechanisms underlying these tumors.
Another reason for the low sensitivity could be molecularly inappropriate patient selection. We might have overestimated HER2 IHC positivity because in the present study, we used the scoring system for IHC status that is applied to gastric cancer, which is less strict than 
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Regarding HER2-mutant tumors, we designed this study to limit the types of mutations to those confirmed as driver oncogenes in previous reports 4 but did not exclude tumors with co-mutation in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA); such mutation was reported as a potential intrinsic resistance mechanism, possibly leading to the low sensitivity.
The current study had several limitations. First, it used a single-arm design, and various potential biases could not be eliminated. Additionally, the study comprised a small number of patients recruited from only a few institutes in one country, thus lowering the likelihood of confirmative results. The relationship between type of HER2 mutations and efficacy also remains unknown. Our study results should be interpreted together with those of relevant previous studies (see Supplementary Table 1 ).
In conclusion, T-DM1 showed limited efficacy against HER2-positive NSCLCs in our cohort. It seems that the concept of precision medicine is difficult to apply to tumors. Additional molecular approaches are warranted for precision medicine in the treatment of HER2-positive tumors. 
